RBM3 in Testicular Cancer Diagnostics and Prognostics

Abstract

The present disclosure provides a method for determining whether a mammalian subject belongs to a first or a second group, wherein subjects of the first group have a higher risk of having a testicular disorder than subjects of the second group, comprising the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA in at least part of an earlier obtained sample comprising biological material from a testicle of said subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group. Further, a prognostic method for testicular cancer is provided, as well as means and uses with prognostic and diagnostic applications.

Description

[0001]This application is a Continuation-In-Part of PCT / EP2010 / 051935, filed Feb. 16, 2010 which claims priority to PCT / SE2009 / 000091, filed Feb. 16, 2009, U.S. Provisional Application No. 61 / 169,963, filed Apr. 16, 2009, EP09158084.5, filed Apr. 16, 2009, U.S. Provisional Application No. 61 / 233,769, filed Aug. 13, 2009, EP09167847.4, filed Aug. 13, 2009, and PCT / EP2009 / 067419, filed Dec. 17, 2009. The present application also claims priority to U.S. Provisional Application No. 61 / 487,341, filed May 18, 2011 and EP11166558.4, filed May 18, 2011.FIELD OF THE PRESENT DISCLOSURE[0002]The present disclosure relates to the field of testicular cancer. Further, it relates to detection of testicular disorders, including pre-malignant stages of testicular cancer, as well as the establishment of a prognosis for testicular cancer patients.BACKGROUNDCancer[0003]Cancer is one of the most common diseases, and a major cause of death, in the western world. In general, incidence rates increase with ...

AI Technical Summary

Benefits of technology

This approach allows for more accurate stratification of testicular cancer patients, enabling personalized treatment strategies and potentially improving survival rates by ensuring appropriate treatment intensity based on individual prognosis.

Problems solved by technology

No definition of cancer is entirely satisfactory from a cell biological point of view, despite the fact that cancer is essentially a cellular disease and defined as a transformed cell population with net cell growth and anti-social behavior.

This multi-step process includes several rate-limiting steps, such as addition of mutations and possibly also epigenetic events, leading to formation of cancer following stages of precancerous proliferation.

However, most of these analyses still represent basic research and have yet to be evaluated and standardized for the use in clinical medicine.

It shares some similarity with other hormones, and false positives may therefore occur.

Images